MX2020001197A - Tratamiento del cancer mediante la estimulacion de la produccion de interleucina 12 (il-12). - Google Patents

Tratamiento del cancer mediante la estimulacion de la produccion de interleucina 12 (il-12).

Info

Publication number
MX2020001197A
MX2020001197A MX2020001197A MX2020001197A MX2020001197A MX 2020001197 A MX2020001197 A MX 2020001197A MX 2020001197 A MX2020001197 A MX 2020001197A MX 2020001197 A MX2020001197 A MX 2020001197A MX 2020001197 A MX2020001197 A MX 2020001197A
Authority
MX
Mexico
Prior art keywords
production
stimulation
cancer
treatment
oxopyridin
Prior art date
Application number
MX2020001197A
Other languages
English (en)
Inventor
David Festus Charles Moffat
Martin John Perry
Stephen Mark Anderton
Clare Louise Doris
Original Assignee
Macrophage Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Macrophage Pharma Ltd filed Critical Macrophage Pharma Ltd
Publication of MX2020001197A publication Critical patent/MX2020001197A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)

Abstract

La presente invención se refiere a un compuesto y composición para usarse en la estimulación de la producción de IL-12 y la producción de IFN-?, cuyo compuesto se selecciona de: N-[2-{4-[6-amino-5-(2,4-difluorobenzoil)-2-oxopiridin-1(2H)-il]-3 ,5-difluorofenil)etil)-L-alaninato de terc-butilo, o una sal, hidrato o solvato del mismo farmacéuticamente aceptable; y el N-[2-{4-[6-amino-5-(2,4-difluorobenzoil)-2-oxopiridin-1(2H)-il]-3 ,5-difluorofenil)etil)-L-alanina.
MX2020001197A 2017-08-31 2018-08-30 Tratamiento del cancer mediante la estimulacion de la produccion de interleucina 12 (il-12). MX2020001197A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1713975.9A GB201713975D0 (en) 2017-08-31 2017-08-31 Medical use
PCT/GB2018/052448 WO2019043389A1 (en) 2017-08-31 2018-08-30 TREATMENT OF CANCER BY STIMULATING IL-12 PRODUCTION

Publications (1)

Publication Number Publication Date
MX2020001197A true MX2020001197A (es) 2020-08-13

Family

ID=60050569

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020001197A MX2020001197A (es) 2017-08-31 2018-08-30 Tratamiento del cancer mediante la estimulacion de la produccion de interleucina 12 (il-12).

Country Status (15)

Country Link
US (1) US11382902B2 (es)
EP (1) EP3675851A1 (es)
JP (1) JP2020536848A (es)
KR (1) KR20200129086A (es)
CN (1) CN111356457A (es)
AU (1) AU2018326668A1 (es)
BR (1) BR112020003033A2 (es)
CA (1) CA3071550A1 (es)
GB (1) GB201713975D0 (es)
IL (1) IL272769A (es)
MA (1) MA50030A (es)
MX (1) MX2020001197A (es)
RU (1) RU2020111355A (es)
SG (1) SG11202000565VA (es)
WO (1) WO2019043389A1 (es)

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU650953B2 (en) 1991-03-21 1994-07-07 Novartis Ag Inhaler
FR2790960B1 (fr) * 1999-03-15 2002-10-31 Pf Medicament Utilisation de fractions membranaires bacteriennes a activite immunostimulante dans le traitement de cancers, leurs procedes de preparation et les compositions pharmaceutiques les contenant
WO2003068746A1 (en) 2002-02-11 2003-08-21 Bayer Pharmaceuticals Corporation Aryl ureas as kinase inhibitors
ATE485275T1 (de) 2002-02-12 2010-11-15 Glaxosmithkline Llc Nicotinamide und deren verwendung als p38 inhibitoren
BR0308429A (pt) 2002-03-14 2005-01-11 Bayer Healthcare Ag Aroilpiridinonas monocìclicas como agentes antiinflamatórios
US20060079461A1 (en) * 2003-12-24 2006-04-13 Scios, Inc. Treatment of multiple myeloma by inhibition of p38 MAP kinase
GB0509223D0 (en) 2005-05-05 2005-06-15 Chroma Therapeutics Ltd Enzyme inhibitors
GB0509225D0 (en) 2005-05-05 2005-06-15 Chroma Therapeutics Ltd Inhibitors of enzymatic activity
GB0509227D0 (en) 2005-05-05 2005-06-15 Chroma Therapeutics Ltd Intracellular enzyme inhibitors
WO2006117567A2 (en) 2005-05-05 2006-11-09 Chroma Therapeutics Ltd Alpha aminoacid ester-drug conjugates hydrolysable by carboxylesterase
GB0510204D0 (en) 2005-05-19 2005-06-22 Chroma Therapeutics Ltd Enzyme inhibitors
GB0608837D0 (en) 2006-05-04 2006-06-14 Chroma Therapeutics Ltd Inhibitors of MAP kinase
GB0608823D0 (en) 2006-05-04 2006-06-14 Chroma Therapeutics Ltd Inhibitors of P13 kinase
GB0608821D0 (en) 2006-05-04 2006-06-14 Chroma Therapeutics Ltd DHFR enzyme inhibitors
CA2650970C (en) 2006-05-04 2014-09-16 Chroma Therapeutics Ltd. P38 map kinase inhibitors
GB0619753D0 (en) 2006-10-06 2006-11-15 Chroma Therapeutics Ltd Enzyme inhibitors
JP2010507639A (ja) 2006-10-25 2010-03-11 クロマ セラピューティクス リミテッド 癌の治療に有用なポロ様キナーゼ阻害剤としてのプテリジン誘導体
GB0621203D0 (en) 2006-10-25 2006-12-06 Chroma Therapeutics Ltd PLK inhibitors
BRPI0622100A2 (pt) 2006-10-30 2011-12-27 Chroma Therapeutics Ltd hidroxamatos como inibidores de desacetilase de histona
AU2007315943A1 (en) 2006-11-01 2008-05-08 Chroma Therapeutics Ltd. IKK-beta serine-threonine protein kinase inhibitors
WO2008053185A1 (en) 2006-11-01 2008-05-08 Chroma Therapeutics Ltd. INHIBITORS OF IKK-β SERINE-THREONINE PROTEIN KINASE
JO2985B1 (ar) 2006-12-20 2016-09-05 Takeda Pharmaceuticals Co مثبطات كينازmapk/erk
WO2009060160A1 (en) 2007-11-07 2009-05-14 Chroma Therapeutics Ltd. P38 map kinase inhibitors
GB0803747D0 (en) 2008-02-29 2008-04-09 Martin Enzyme and receptor modulation
EP2245012B1 (en) 2008-02-29 2013-07-03 Chroma Therapeutics Limited Inhibitors of p38 map kinase
EA201001694A1 (ru) 2008-04-23 2011-06-30 Хрома Терапьютикс Лтд. Ингибиторы ikk-бета серин-треонин протеинкиназ
GB0807451D0 (en) 2008-04-24 2008-05-28 Chroma Therapeutics Ltd Inhibitors of PLK
BRPI0911480A2 (pt) 2008-04-26 2018-04-03 Chroma Therapeutics Ltd inibidores de proteínas serina-treonina quinase ikk-beta
GB0903480D0 (en) 2009-02-27 2009-04-08 Chroma Therapeutics Ltd Enzyme Inhibitors
GB0907120D0 (en) 2009-04-24 2009-06-03 Chroma Therapeutics Ltd Inhibitors of IKK-ß serine-threonine protein kinase
GB201009853D0 (en) 2010-06-11 2010-07-21 Chroma Therapeutics Ltd HSP90 inhibitors
GB201021467D0 (en) 2010-12-17 2011-02-02 Chroma Therapeutics Ltd Imaging agents
JP6005751B2 (ja) * 2011-10-21 2016-10-12 トランジェーヌ、ソシエテ、アノニムＴｒａｎｓｇｅｎｅ Ｓ．Ａ． マクロファージの活性化の調節
GB201211310D0 (en) 2012-06-26 2012-08-08 Chroma Therapeutics Ltd CSF-1R kinase inhibitors
US9388136B2 (en) * 2012-10-17 2016-07-12 Chroma Therapeutics Ltd Tert-butyl N-[2-{4-[6-amino-5-(2,4-difluorobenzoyl)-2-oxopyridin-1(2H)-yl]-3,5-difluorophenyl}ethyl]-L-alaninate or a salt, hydrate or solvate thereof
GB201306901D0 (en) * 2013-04-16 2013-05-29 Chroma Therapeutics Ltd Combination

Also Published As

Publication number Publication date
RU2020111355A (ru) 2021-09-30
SG11202000565VA (en) 2020-03-30
US20200360359A1 (en) 2020-11-19
EP3675851A1 (en) 2020-07-08
BR112020003033A2 (pt) 2020-08-04
AU2018326668A1 (en) 2020-02-20
WO2019043389A1 (en) 2019-03-07
JP2020536848A (ja) 2020-12-17
RU2020111355A3 (es) 2021-12-16
CA3071550A1 (en) 2019-03-07
MA50030A (fr) 2020-07-08
IL272769A (en) 2020-04-30
KR20200129086A (ko) 2020-11-17
CN111356457A (zh) 2020-06-30
GB201713975D0 (en) 2017-10-18
US11382902B2 (en) 2022-07-12

Similar Documents

Publication Publication Date Title
MX2020002060A (es) Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos.
PH12021550045A1 (en) 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
PH12019500480A1 (en) Pyridine compound
PH12019501985A1 (en) Fused imidazo-piperidine jak inhibitors
PH12019500395A1 (en) Amino-pyrrolopyrimidinone compounds and methods of use thereof
MD4800C1 (ro) Compuşi de aminopirimidinil ca inhibitori de JAK
MY196836A (en) Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (dub) inhibitors
PH12018500828A1 (en) Jak kinase inhibitor compounds for treatment of respiratory disease
MX2017004234A (es) Inhibidor del egfr y preparacion y aplicacion del mismo.
MX2021002521A (es) Dimetilaminoazetidinaminas como inhibidores de jak.
SG11201806930PA (en) Novel condensed pyrimidine compound or salt thereof
SG10201811384TA (en) Mnk inhibitors and methods related thereto
SG11201901061QA (en) Heterocyclic compound
MX2013011589A (es) Metodos y composiciones para tratar enfermedad de parkinson.
TN2020000081A1 (en) Amino-methyl piperidine derivative as kinase inhibitor
NZ711424A (en) Pyridine derivatives as soft rock inhibitors
PH12019502345A1 (en) Methods of treatment using a jak inhibitor compoud
EA033168B1 (ru) СТИМУЛЯТОРЫ sGC
EA034243B9 (ru) Фармацевтические композиции, содержащие azd9291, для лечения рака
MY194468A (en) Oxy-fluoropiperidine derivatives as kinase inhhiitor
ZA202100990B (en) 5 to 7 membered heterocyclic amides as jak inhibitors
MX2022005298A (es) Compuestos intermediarios de sintesis de inhibidores de a2a.
PH12019550217A1 (en) Novel dual mode of action soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof
SA519401322B1 (ar) مركبات أريل كربوكساميد غير متجانسة كمثطبات لكيناز بروتين سيرين/ ثريونين متداخل مع المستقبل 2
MX2017012600A (es) Composicion y proceso para tratar el cabello.